Med. praxi. 2012;9(10):379-381

Effective drug therapy of liver diseases in general practice

doc.MUDr.Radan Brůha, CSc.
IV. interní klinika 1. LF UK a VFN, Praha

Pharmacotherapy of liver diseases moves from symptomatic treatment toward the specific treatment. Only methods based on relevant

clinical studies should be used. This condition does not fill previously widely prescribed “hepatoprotectives”. Apart from viral hepatitis, in

clinical praxis we usually deal with alcoholic liver disease, non alcoholic steatohepatitis, chronic cholestatic syndromes and complications

of liver cirrhosis. Basic treatment in alcoholic and non alcoholic liver disease is life style changes and diet, in the treatment of chronic

cholestasis ursodeoxycholic acid is used. In the treatment of liver cirrhosis pharmacologic prevention of variceal bleeding, prevention

of infections and diuretic treatment of ascites improve prognosis and quality of life. The effect of many supportive medicaments with

antioxidant or other protective properties was not proved.

Keywords: alcoholic liver disease, hepatoprotectives, cholestasis, liver cirrhosis, NASH

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brůha R. Effective drug therapy of liver diseases in general practice. Med. praxi. 2012;9(10):379-381.
Download citation

References

  1. Tilg H, Day C. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 24-34. Go to original source... Go to PubMed...
  2. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver diseases: a systematic review and metaanalysis. Am J Med 2002; 113: 506-515. Go to original source... Go to PubMed...
  3. Plauth M, Cabré E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J. DGEM (German Society for Nutritional Medicine), Ferenci P, Holm E, Vom Dahl S, Müller MJ, Nolte W, ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006; 25: 285-294. Go to original source... Go to PubMed...
  4. Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008; 47: 746-754. Go to original source... Go to PubMed...
  5. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 2010; 362: 1675-1685. Go to original source... Go to PubMed...
  6. Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J Hepatol 2011; Apr 14 [Epub ahead of print]. Go to original source... Go to PubMed...
  7. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomzed controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-1090. Go to original source... Go to PubMed...
  8. Musso G, Bambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104. Go to original source... Go to PubMed...
  9. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liv Dis 2008; 40: 194-199. Go to original source... Go to PubMed...
  10. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids in Health and Disease 2011; 10: 49. Go to original source... Go to PubMed...
  11. Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 1529-1538. Go to original source... Go to PubMed...
  12. Gong Y, Huang ZB, Christensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2008; 16(3): CD000551. Go to original source... Go to PubMed...
  13. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-1472. Go to original source... Go to PubMed...
  14. Lindor KD, Kowdley KV, Luketic VAC, Harrison ME, McCashland T, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814. Go to original source... Go to PubMed...
  15. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJV, Planas R, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol, 2000; 32: 142-153. Go to original source... Go to PubMed...
  16. Alaniz C, Regal RE. Spontaneous Bacterial Peritonitis: A Review of Treatment Options. Pharmacy and Therapeutics. 2009; 34: 204-210. Go to PubMed...
  17. de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010; 53: 762-768. Go to original source... Go to PubMed...
  18. Gines P, Angeli P, Lenz K, Moller S, Moore K, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417. Go to original source... Go to PubMed...
  19. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009; 50: 1294-1306. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.